Dr. Henry has worked in therapeutics development for more than 20 yrs. He is co-founder of Kuria Therapeutics and serves as CTO to develop ophthalmic therapies that address mitochondrial dysfunction, which is the root cause of age-related diseases in the front and back of the eye. He is also co-founder and EVP at InterveXion Therapeutics where his efforts support manufacturing and testing of InterveXion’s protein therapies for ongoing clinical evaluation.  As a Distinguished Professor at University of Arkansas, his collaborative team made breakthroughs in protein production technologies and in protein targeting. Dr. Henry also uses his experience to support VIC Technology Venture Development in identifying medical and life sciences technologies suitable for commercial development.